Safety and Feasibility of Accelerated Pembrolizumab and Nivolumab Infusions: A Quality Improvement Initiative (Medscape) - Sep 17, 2026 - "This retrospective chart review included patients treated between January 21 and March 20, 2026, who received at least 1 standard rate infusion (average cycle #10) followed by accelerated infusion(s)....Forty-two patients (average age 74; ECOG 2; 41 male) received 60 accelerated infusions. Most received pembrolizumab (n=39) and 3 received nivolumab. A single IRR occurred (1.66%), presenting as asymptomatic grade 3 hyper-tension requiring no intervention; subsequent accelerated infusion was tolerated. No delayed IRRs were documented. Accelerated infusions saved 1,200 minutes (20 hours) of chair time and approximately $1,000 in nursing infusion time cost."
Retrospective data • Oncology
|